Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
Phase 4 Study of PPSV23 Pneumococcal Vaccine in COPD Patients Using High Daily Dose of Inhaled Corticosteroid
Streptococcus pneumoniae is the most common causes of community-acquired pneumonia and exacerbations in chronic obstructive pulmonary disease (COPD) patients, which are associated with morbidity, mortality, and higher health-care cost. In addition, recently high daily dose of inhaled corticosteroid (ICS) therapy became more evident to be beneficial in moderate-to-severe COPD patients, but excess risk of pneumonia shown in database analysis was worried about by primary physicians. The use of pneumococcal polysaccharide vaccination (PPSV23) has protective efficacy to eliminate infection of Streptococcus pneumoniae from previous studies. If the use of PPSV23 can reduce the incidence of pneumonia or exacerbations in COPD patients using high daily dose of ICS, the benefit of ICS can be preserved and risk of pneumonia can be reduced. However, there is only limited data supporting this hypothesis. In this study, the investigators will conduct a double-blinded, randomized controlled trial to evaluate the clinical efficacy of PPSV23 in severe COPD patients using high daily dose of ICS.
Exacerbations are a common feature in moderate-to-severe chronic obstructive pulmonary
disease (COPD). Morbidity, mortality and health-care costs of these patients largely result
from exacerbations. The most common causes of an exacerbation are infection of
tracheobronchial tree. Among them, Streptococcus pneumoniae is the most frequently isolated
organism, accounting for 5-25% patients of COPD, while it is also the most commonly
identified cause in community-acquired pneumonia (CAP), accounting for 16.5-38.9% of CAP
patients.
In recent years, widespread emergence of antimicrobial resistance in Streptococcus
pneumoniae has became a major global concern, especially in Taiwan, one of the highest
levels of antibiotic-resistant pneumococci in the world. Therefore, primary prevention by
vaccination is encouraged for those high-risk patients with COPD. The currently available
adult pneumococcal vaccine consists of the capsular polysaccharide of 23 different serotypes
of Streptococcus pneumoniae (PPSV23). The antibodies produced in response to this
polysaccharide can provide protection by inducing host immune cells to kill or to opsonize
bacteria for phagocytosis.
Until now, few studies have been designed to specifically examine vaccine efficacy in COPD
patients. Among 3 available randomized controlled trials, only one study involving 596
patients found, from post-hoc analyses, some protective efficacy for pneumonia in patients
of < 65 years of age and of an FEV1 < 40% predicted. Based on above evidence (only limited
body of data), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2006
Guideline has recommended the PPSV23 inoculation as evidence B.
By the way, in comparison to placebo and the single components, a superior control by means
of the inhaled corticosteroids (ICS)/long-acting beta2-agonist (LABA) fixed combination
therapy has been demonstrated for significant clinical improvement in moderate-to-severe
COPD patients, except mortality, by meta-analysis and large prospective studies (TORCH
[Towards a Revolution in COPD Health] trial and INSPIRE [Investigating New Standards for
Prophylaxis in Reduction of Exacerbations] trial). However, those database indicated that
high daily dose of ICS (fluticasone propionate at a dose of 500-1000mcg daily) was
associated with an excess risk of pneumonia, which doubles the pneumonia incidence in
patients not receiving ICS. The immunogenicity of PPSV23 in COPD patients using systemic
steroid was demonstrated but the clinical efficacy of vaccination has not been investigated.
From above-mentioned background, if the use of PPSV23 can reduce the incidence of pneumonia
or exacerbations in COPD patients using high daily dose of ICS, the benefit of ICS can be
preserved and risk of pneumonia can be reduced. For primary physicians, this hypothesis, if
true, is very beneficial. So, in this study, the investigators want to conduct a
double-blinded, randomized controlled trial to evaluate the clinical efficacy of PPSV23 in
COPD patients using high daily dose of ICS.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|